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Abstract
Background: Hydroxyethyl starch (HES) is used for repletion of acute intravasal volume loss in surgical patients.
However, in critically ill patients, HES is associated with acute kidney injury. We aimed to evaluate the effect of HES
on perioperative cystatin C (cystC)-derived estimated glomerular filtration rates (eGFRcystC) in patients undergoing
open and robot-assisted radical prostatectomy.
Methods: In this retrospective study we included 179 patients who underwent general anaesthesia for radical
prostatectomy, received HES perioperatively, and had complete cystC and fluid therapy data available. CystC and
corresponding eGFRcystC at postoperative days 1, 3, and 5 were compared with preoperative baseline using
Wilcoxon rank-sum test.
Results: In 179 eligible patients, 6 % HES 130/0.4 was administered in a median (25th to 75th percentile) dose of
1000 mL (1000 to 1000 mL). Baseline eGFRcystC was 109.4 mL/min (100.3 to 118.7 mL/min). eGFRcystC on
postoperative days 1, 3, and 5 was 120.4 mL/min (109.4 to 134.0 mL/min), 120.4 mL/min (109.4 to 132.9 mL/min),
and 117.9 mL/min (106.6 to 129.8 mL/min), respectively (p < 0.001 compared with baseline, each). No patient had
an eGFRcystC-decrease of ≥25 % from baseline.
Conclusions: The results indicate that the administration of a median dose of 1000 mL of 6 % HES 130/0.4 is not
associated with a postoperative deterioration of renal function in patients with normal to near-normal baseline
renal function undergoing radical prostatectomy.
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Background
Postoperative acute kidney injury (AKI) is highly preva-
lent [1] and associated with increased hospital mortality
[2]. Multiple factors contribute to AKI, e.g. the type of
surgery and haemodynamic instability [3]. Moreover, re-
cent studies suggested that the administration of fluids
containing hydroxyethyl starch (HES) leads to a moder-
ately increased risk of AKI and increased requirement of
renal replacement therapy in critically ill patients [4–6].
In the operative setting, on the contrary, this connection
is currently not clearly evident [7]. In patients undergo-
ing major surgery, prospective studies did not show a
considerable effect of perioperatively administered HES
on estimated glomerular filtration rate (eGFR) calculated
based on serum creatinine (sCr) [8–10].
Similar results were obtained when using the more
sensitive [11, 12] glomerular filtration rate (GFR)-marker
cystatin C (cystC) [13, 14]. Therefore, a possible context-
dependency (i.e. elective surgery vs. critical illness) of
the degree of apparent adverse effects of HES on kidney
function may exist.
We hypothesised that perioperative administration of
HES for the replacement of acute intravasal volume loss
due to intraoperative haemorrhage does not lead to clin-
ically relevant impairment of eGFR in a population of
elective surgical patients without marked a priori risk of
AKI. This in itself would be an important finding for a
more detailed understanding of differential indications
and contraindications of HES.
Therefore, we evaluated the influence of periopera-
tively administered HES on eGFR determined by se-
quential cystC measurements (eGFRcystC) in a general
patient population undergoing open radical prostatec-
tomy (ORP) or robot-assisted radical prostatectomy




The study protocol of this retrospective analysis (ethics
committee number PV4998) was reviewed and approved
by the appropriate ethics committee (Ethikkommission
der Ärztekammer Hamburg, Hamburg, Germany). Due
to the retrospective nature of the study and the anon-
ymisation of data the need for informed consent was
waived by the ethics committee.
To evaluate the influence of perioperatively administered
HES on eGFRcystC in patients undergoing ORP or RARP,
we retrospectively extracted and analysed data from the
hospital-wide digital patient record system that included
biometric, medical, procedural, and physiologic parameters
of patients in whom perioperative cystC measurements had
been performed during their hospitalisation for ORP or
RARP between September 2012 and April 2013.
Patients; inclusion/exclusion criteria
Patients were eligible for study inclusion if they a) had
undergone general anaesthesia for ORP or RARP (with-
out the need for a re-intervention within 5 days from
the original operation), b) had received HES periopera-
tively, c) had cystC measurements recorded in their elec-
tronic hospital charts (at least one cystC value measured
preoperatively (baseline) and at least one cystC value
measured on days 1 or 3), and d) had complete docu-
mentation of perioperative fluid therapy in the digital
patient record system.
Data acquisition
We extracted data on the type of radical prostatectomy
(ORP vs. RARP), duration of surgery, intraperitoneal pres-
sure (in RARP), and estimated intraoperative blood loss
from surgical records. Biometric and medical status data,
including relevant pre-existing co-morbidities and long-
term medication, were obtained from preoperative anaes-
thesiological evaluation notes. For the operative period
(including post anaesthesia care unit), we extracted data
from the corresponding anaesthesia records. Laboratory
data were extracted from the digital patient record system
for preoperative baseline and days 1, 3, and 5. Baseline
systolic arterial blood pressure (SAP) was defined as the
first SAP measurement at the time of the patients’ arrival
in the anaesthesia induction area. Doses of norepinephrine
were expressed as the maximum infusion rate during the
time under anaesthetic care. For perioperative fluid and
volume therapy, the colloid 6 % HES 130/0.4 (Vololyte®;
Fresenius Kabi Deutschland GmbH, Bad Homburg,
Germany) and the balanced full electrolyte solution (Ster-
ofundin®; B. Braun Melsungen AG, Melsungen, Germany)
were used. The documented units of intravenous fluids
(i.e. crystalloids, colloids, or blood products) were as-
sumed to be administered completely without residue.
Calculation of estimated glomerular filtration rate from
serum cystatin C
For the calculation of eGFRcystC, we used the formula
previously published by Le Bricon and colleagues: [15].
eGFRcystC (mL/min) = 78 × cystC [mg/L]
−1 + 4.
For eGFR derived from concomitant sCr measurements
(eGFRcrea), we applied the simplified Modification of Diet
in Renal Disease (MDRD-4)-formula: [16].
eGFRcrea (mL/min) = 186 × sCr [mg/dL]
-1,154 × age [yrs]-
0,203, corrected for sex and race (× 1, if male Caucasian). If
not stated in the patient records, the patient’s race was as-
sumed to be Caucasian. All eGFRx-values stated in this
publication are normalised for 1.73 m2 body surface area.
Statistical analysis
We present descriptive statistical analyses as median
(25th to 75th percentile range) for continuous data and
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as absolute frequencies with percentages for categorical
data. Within-group differences were evaluated using
Wilcoxon rank-sum test for paired non-parametric data.
Box-whisker-plots were created for illustration of chosen
non-parametric data. For data management we used
Microsoft Excel 2010 (Microsoft Corp., Redmond, WA,
USA) and for statistical analyses and figures we used
IBM SPSS Statistics, Version 21.0 (IBM Corp., Armonk,
NY, USA).
Cases, in which data were missing, were excluded in
the respective analysis. Statistical significance was as-
sumed for p < 0.05.
Results
Patients
In this study we analysed 179 patients (Fig. 1). Of note,
8 Patients were excluded a priori who did not receive
HES perioperatively. We present the patients’ character-
istics in Table 1.
Procedural data
Procedural data of the study population, including
haemodynamic therapy, are presented in Table 2.
The median dose of administered HES was 1000 mL
(1000 to 1000 mL). All patients additionally received
crystalloid solution with a median dose of 3500 mL
(2500 to 3500 mL).
Renal function
We show data on baseline renal function and renal func-
tion on postoperative days 1, 3, and 5 in Table 3 and
Figs. 2a, b, 3a, and b. Postoperative cystC values were
available for 1, 2, and 3 postoperative days in 12 (6.7 %),
53 (29.6 %), and 114 (63.7 %) patients, respectively.
The number of patients with increases in cystC and de-
creases in eGFRcystC of ≥5 % and of ≥10 % on either of the
postoperative days 1, 3, or 5, compared with the preopera-
tive baseline values were 21 (11.7 %) and 9 (5.0 %) patients,
respectively, and 20 (11.2 %) and 7 (3.9 %) patients, respect-
ively. No patient had a preoperative baseline eGFRcystC
value below 60 mL/min. Of note, there was no patient with
an increase in cystC or decrease in GFRcystC of ≥25 %.
Compared with the median baseline values there was a
statistically significant decrease in median cystC values
and a statistically significant increase in median eGFRcystC
values on postoperative day 1, 3, and 5 (p < 0.001, each).
Fig. 1 Patient flow diagram. Illustration of patient exclusion
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There was no statistically significant difference be-
tween median sCr and eGFRcrea values on postoperative
days 1, 3, and 5 compared with baseline.
Discussion
The results of this retrospective analysis indicate that
the administration of a median dose of 1000 ml 6 %
HES 130/0.4 is not associated with a postoperative de-
terioration of renal function in terms of a decrease in
eGFRcystC in patients with normal to near-normal base-
line renal function undergoing radical prostatectomy.
Compared with sCr, CystC is a more accurate and pre-
cise estimator of a near-normal eGFR from 60 to 90 mL/
min [17, 18]. It further exhibits a higher sensitivity for
eGFR-changes [11, 12]. Thus, it may detect postopera-
tive AKI earlier as opposed to sCr [19], i.e. as early as
one day postoperatively with peak values on day three
[20]. Therefore, a possible increase in cystC due to
surgery-related AKI should have likely been detected by
cystC-measurements during the observed time span in
this study.
There are some, mainly smaller clinical studies using
cystC for the investigation of the effect of perioperative
6 % HES 130/0.4 on renal function in individuals with-
out acute systemic disease. In a randomised controlled
trial (RCT), Mukhtar and colleagues tested 6 % HES
Table 1 Patient characteristics
Parameter, unit Value
Age, yrs 64 (59 to 69)
Weight, kg 83.0 (76.0 to 90.0)
Height, m 1.8 (1.75 to 1.83)








Chronic arterial hypertension 80 (44.7)
Chronic heart failure 1 (0.6)
Coronary artery disease 7 (3.9)
Cerebrovascular disease 11 (6.1)
Periphery artery disease 1 (0.6)
Atrial fibrillation 6 (3.4)
Chronic kidney disease 1 (0.6)
Diabetes mellitus 14 (7.8)
Rheumatoid arthritis 2 (1.1)
Long-term Medication
Diuretic (thiazide, indapamid) 17 (9.5)
Diuretic (K+-sparing) 2 (1.2)









Data presented as median (25th to 75th percentile) or number of cases (%)
ASA American Society of Anesthesiologists, ACE angiotensin-converting-
enzyme, AT1 angiotensin-receptor-1, NSAID non-steroidal
anti-inflammatory drug
Table 2 Procedural data
Parameter, unit Value
Operation
Robot-assisted radical prostatectomy 69 (38.5)
Open radical prostatectomy 110 (61.5)
Duration of surgery, min 190 (164 to 225)
Intraperitoneal pressure, if applicable, mmHg 15 (15 to 15)
Mode of anaesthesia
Total intravenous 86 (48.0)
Balanced 93 (52.0)
Spinal (combined) 72 (40.2) (all ORP)
Haemodynamic data
Blood loss (intraoperative), mL 500 (250 to 800)
Diuresis in PACU, mL 800 (550 to 1200)
Pre-induction SAP, mmHg 130 (120 to 140)
SAP≤ 100 mmHg 174 (97.2)
SAP≤ 90 mmHg 104 (58.1)
SAP≤ 80 mmHg 38 (21.2)
SAP≤ 70 mmHg 7 (3.9)
SAP≤ 60 mmHg 1 (0.6)
Haemodynamic therapy
HES solution, mL 1000 (1000 to 1000)
Crystalloid solution, mL 3500 (2500 to 3500)
Cases administered RCCs 4 (2.3)
Number of RCCs, if administered 2.0 (1.3 to 2.0)
Cases administered FFPs 0 (0.0)
Cases administered PCs 0 (0.0)
Maximum norepinephrine dose, μg/min 6.0 (5.0 to 9.0)
Data presented as median (25th to 75th percentile) or number of cases (%)
ORP open radical prostatectomy, PACU post anaesthesia care unit, SBP systolic
arterial blood pressure, HES hydroxyethyl starch, RCC red cell concentrate,
FFP fresh frozen plasma, PC platelet concentrate
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130/0.4 against human 5 % albumin in 40 living donor
liver transplant recipients and found no difference in the
perioperative course of cystC as well as creatinine clear-
ance [14]. Harten and colleagues analysed data from 29
patients undergoing emergency abdominal surgery in
their pilot RCT to investigate the influence of goal di-
rected haemodynamic therapy on kidney function using
6 % HES 130/0.4 in the intervention group vs. usual care
for the control-group, while the latter received unspeci-
fied colloids different than HES. In their study, there
was no statistically significant difference in cystC or sCr
between groups [21]. These findings as well as our own
results provide some evidence that there are no harmful
effects of HES on the GFR in surgical patients in the ab-
sence of critical illness.
These findings are in line with a study analysing kid-
ney biomarkers other than cystC in 40 patients undergo-
ing ORP randomised to receive either 6 % HES 130/0.4
or 0.9 % saline perioperatively [22]. In this study, there
was no deleterious effect in the HES compared to the
normal saline group with regard to sCr, creatinine clear-
ance, neutrophil gelatinase associated lipocalin, as well
as the markers of the renin-angiotensin-aldosterone-
pathway [22].
A meta-analysis of 19 RCTs including studies on the
influence of various 6 % HES solutions on hospital mor-
tality and AKI or renal replacement therapy in surgical
patients revealed no statistically significant differences in
outcomes in the patients receiving HES compared to the
patients receiving the respective alternative solutions [7].
Our results show, that there is not only no increase in
cystC levels from baseline values, but that there is even
a decrease in cystC. We did not expect the correspond-
ing eGFRcystC to increase in the context of major sur-
gery, which is associated with blood loss and
catecholamine use. To offer an explanation, a recent
study with healthy volunteers showed that infusion of
fluids, including 6 % HES 130/0.4, even though net
cystC serum content rises, leads to a dilution of serum
cystC concentration early after the infusion [23]. How-
ever, as 6 % HES 130/0.4 has a terminal half-life of
16.1 h independent of the degree of pre-existing renal
impairment [24], in theory, postoperatively rather than
intraoperatively infused fluids may have caused such an
effect on cystC on day 3 or 5 postoperatively. Moreover,
it has been shown that an increase in extracellular fluid
volume leads to increased GFR above baseline values in
patients without renal impairment, partly compensating
for the extracellular fluid increase, as long as the patients
do not exhibit increased extracellular volume at baseline
due to fluid overload caused by pre-existing chronic kid-
ney disease [25]. A relatively high ratio of administered
fluid volume and blood loss in our patients may have led
to this dilution effect. This may be interpreted as an
acute compensatory increase in GFR in patients without
kidney disease as well as falsely high postoperative
eGFRcystC values as a result of a dilution effect on cystC
serum concentration.
Risk factors for postoperative AKI have been identified
for general surgical [3] as well as urological [26] patients.
While urological surgery per se is frequently associated
with AKI, the patient subgroup studied here is at no par-
ticularly increased risk.
Previous clinical trials have demonstrated adverse ef-
fects of HES on renal function and need for renal re-
placement therapy in patients with severe sepsis [4–6]
which has led to the extension of the contraindications
of HES for critically ill patients in general [27,28]. More-
over, concerns have been raised, that the use of HES in
Table 3 Renal function
Parameter, unit Number of patients
with available data, n
Value
Graded baseline eGFRcystC, n 179
≥ 90 mL/min 157 (87.7)
60–89 mL/min 22 (12.3)
30–59 mL/min 0 (0.0)
15–29 mL/min 0 (0.0)
< 15 mL/min 0 (0.0)
Serum cystatin C, mg/L
Preoperative baseline 179 0.74 (0.68 to 0.81)
Postoperative day 1 171 0.67 (0.60 to 0.74)*
Postoperative day 3 157 0.67 (0.61 to 0.74)*
Postoperative day 5 132 0.69 (0.62 to 0.76)*
Serum creatinine, mg/dL
Preoperative baseline 179 1.00 (0.80 to 1.10)
Postoperative day 1 178 0.90 (0.80 to 1.10)
Postoperative day 3 163 0.90 (0.80 to 1.00)
Postoperative day 5 136 0.90 (0.90 to 1.00)
eGFRcystC, mL/min
Preoperative baseline 179 109.4 (100.3 to 118.7)
Postoperative day 1 171 120.4 (109.4 to 134.0)*
Postoperative day 3 157 120.4 (109.4 to 132.9)*
Postoperative day 5 132 117.9 (106.6 to 129.8)*
eGFRcrea, mL/min
Preoperative baseline 179 83.4 (72.1 to 100.4)
Postoperative day 1 178 88.3 (72.0 to 101.1)
Postoperative day 3 163 88.4 (77.9 to 102.5)
Postoperative day 5 136 88.0 (77.9 to 94.5)
Graded eGFRcystC = number of patients with preoperative baseline eGFRcystC
values within one of the listed ranges (no patient has a preoperative baseline
eGFRcystC-value below 60 mL/min; eGFRcystC = serum cystatin C-derived and
eGFRcrea = serum creatinine-derived glomerular filtration rate. All values are
presented as median (25th to 75th percentile)
*p < 0.001 vs. preoperative baseline
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patients without severe systemic disease may be unsafe,
as well [29], however, convincing evidence concerning
this matter is still lacking. The main result of the current
study, along with other studies, builds the hypothesis
that there may be a differential effect of HES on GFR de-
pending on the study population and the clinical
context.
Our study has several limitations. The retrospective
nature of the study is a major limitation of our study
and might restrict generalisability of the results. In
addition, we made the assumption that all bags of fluids
and blood products were infused or transfused entirely.
In addition, it was assumed that all patients were of
Caucasian ethnicity. None of the patients in this study
exhibited a perioperative rise in cystC, where the corre-
sponding fall in eGFRcystC would be considered relevant
for the diagnosis of AKI according to Risk, Injury, Fail-
ure, Loss, and End-stage kidney disease (RIFLE) classifi-
cation criteria [30]. As a result, further analyses aiming
at identifying possible influencing factors on periopera-
tive AKI are inapplicable. This study solely focused on
eGFR as a parameter of kidney function, while the novel
set of structural biomarkers may be considered useful
for future prospective studies [31]. Due to its
Fig. 2 Box-whisker-plots on perioperative renal function. Illustration of the course of peri-operative a serum cystatin C concentration (cystC) and
b corresponding cystC-derived estimated glomerular filtration rate (eGFRcystC) in patients undergoing radical prostatectomy (open or robot-
assisted). N = 179. Wilcoxon rank-sum test: p < 0.001 for baseline vs. day 1, day 3, day 5, each
Fig. 3 Frequencies of perioperative renal function deterioration. Frequency of maximum perioperative a serum Cystatin C (cystC)-increase and
b cystC-derived estimated glomerular filtration rate (eGFRcystC)-decrease in patients undergoing radical prostatectomy (open or robot-assisted)
on postoperative days 1, 3 or 5. N = 179
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retrospective design, it was not possible to exclude influ-
encing factors on cystC other than the intraoperative
fluid therapy. This study can neither make a statement
on extra-renal side effects of HES in the study popula-
tion (e.g. coagulopathy, oedema, cardiac decompensation
or pruritus) nor on potential benefits from HES (e.g.
haemodynamics, morbidity or mortality), as it was de-
signed to test the hypothesis that HES does not exert
harmful effects on kidney function, hence, no final con-
clusion on the risk/benefit-ratio of HES in this popula-
tion can be given.
Conclusions
In conclusion, our study indicates that the administra-
tion of a median dose of 1000 mL 6 % HES 130/0.4
seems not to be associated with a clinically relevant peri-
operative deterioration of renal function in terms of a
decrease in eGFRcystC in patients with normal to near-
normal baseline renal function undergoing radical pros-
tatectomy. As HES has continued to be in clinical use,
large multicentre randomised controlled trials to con-
firm this notion seem warranted, in which sensitive
markers of kidney function and structure should be used
and potential benefits from HES should also be
considered.
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